ArticleAlzheimer's & dementia (New York, N. Y.)
Integration of blood-based biomarkers and genomic variants identifies individuals with mild cognitive impairment who benefit from multidomain intervention.
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOur recent Japan-Multimodal Intervention Trial for the Prevention of Dementia (J-MINT) trial suggested that multidomain lifestyle interventions may delay cognitive decline. However, substantial interindividual variability in response persists, and identifying individuals more likely to benefit from the intervention remains challenging. Blood-based biomarkers (BBMs), which provide a minimally invasive means of assessing Alzheimer's disease (AD)-related pathological processes, may help identify biologically distinct subgroups of individuals with mild cognitive impairment (MCI).
methodsBlood-based biomarkers-including amyloid-β42/40 ratio, phosphorylated tau-217, neurofilament light chain, and glial fibrillary acidic protein (GFAP)-were measured in J-MINT participants. Hierarchical clustering based on BBM profiles was used to identify biologically defined subgroups. Whole-genome sequencing data were analyzed using genome-wide association analysis (GWAS) to identify genetic variants associated with the BBM-based subgroup. A prediction model for the subgroup assignment was constructed using the associated incorporating the genetic variants, age, sex, and apolipoprotein E4 (
resultsBBM-based clustering identified a subgroup characterized by elevated GFAP and multiple biomarker abnormalities. Within this subgroup, the change in cognitive performance from baseline to 18 months differed significantly between intervention and control groups, with greater decline observed in the control group. GWAS identified four variants showing suggestive association with the subgroup, two of which were located in intronic regions of genes associated with hearing loss ( DISCUSSION: BBM-based clustering identified biologically distinct subgroups among individuals with MCI. The subgroup characterized by multiple biomarker abnormalities and elevated GFAP showed differential cognitive trajectories between the intervention and control groups. These findings suggest that BBMs, potentially in combination with genetic information, may help identify individuals with a more progressive AD-related biological profile who may derive greater benefit from multidomain intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.